Rankings
▼
Calendar
TBPH Q4 2019 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena
TBPH
Theravance Biopharma, Inc.
$697M
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$29M
+87.4% YoY
Gross Profit
$29M
100.0% margin
Operating Income
-$71M
-239.2% margin
Net Income
-$66M
-222.4% margin
EPS (Diluted)
$-1.17
QoQ Revenue Growth
+137.4%
Cash Flow
Operating Cash Flow
-$64M
Free Cash Flow
-$66M
Stock-Based Comp.
$24M
Balance Sheet
Total Assets
$409M
Total Liabilities
$633M
Stockholders' Equity
-$224M
Cash & Equivalents
$58M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$29M
$16M
+87.4%
Gross Profit
$29M
$15M
+95.3%
Operating Income
-$71M
-$63M
-12.7%
Net Income
-$66M
-$50M
-30.7%
Revenue Segments
License
$10M
34%
Co Promote Agreement
$10M
34%
Collaborative Arrangement Revenue
$10M
32%
← FY 2019
All Quarters
Q1 2020 →